Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WEF-001 in advanced KRAS-mutant solid tumors
NCT07148128Phase 2Recruiting
- Start
- Jul 2025
- Primary completion
- Jan 2028
- Modality
- Albumin, Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of WEF-001 in pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), ovarian cancer, cholangiocarcinoma (CCA). Started Jul 2025; status: recruiting.
02
Drugs
WEF-001
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)ovarian cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT07148128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07148128.